Sign in to view content

Bevacizumab-First vs Real-World Cost Outcomes for Diabetic Macular Edema: 2-Year Cost Analysis Modeled on DRCR Protocol AC Results

Dilraj S Grewal, MD, FASRS

Video
Published 2023

Related

Treatment Effect of Intravitreal Aflibercept Injection by Baseline Factors in Moderately Severe-to-Severe NPDR in PANORAMA
Nathan C. Steinle, MD
Annual Meeting Talks
2020
Systemic Adverse Events in Patients With Diabetes Treated With Intravitreal Antivascular Endothelial Growth Factor Injections
Roomasa Channa, MD
Annual Meeting Talks
2023
Diabetic Retinopathy Part I Take-Home Panel
Charles C Wykoff, MD, PhD, FASRS
Annual Meeting Talks
2019

Category: Socioeconomics

See more